

FOR IMMEDIATE RELEASE

**CVie Therapeutics enrolled the 1st patient for
Phase 2b Clinical Trial of Rostafuroxin in Taiwan**

Hong Kong, 22nd December 2015—Lee's Pharmaceutical Holdings Limited ("Lee's or the Group") (Main Board Stock Code: 0950; Website: www.leespharm.com) today announced that, CVie Therapeutics Limited ("CVie"), the Group's subsidiary has successfully enrolled its first patient for its Phase 2b clinical trial of Rostafuroxin in Taiwan.

The Taiwan study (MOHW's Approval Notice No. 1046044455) is a part of global Phase IIb trial of Rostafuroxin. Currently, the Italian arm of the study is still ongoing and has completed its targeted enrollment of 160 patients in November this year.

This is a Phase IIb multi-centers, randomized, comparator-controlled, dose-finding clinical study (Protocol No. CVT-CV-001). The study aims to evaluate the anti-hypertensive effects indifferent doses of Rostafuroxin in comparison with Losartan[®], assessed by office and ambulatory blood pressure monitoring in a hypertensive population selected according to specific genetic profiles. The study involved a total of 17 centers and 18 centers respectively across Italy and Taiwan. The total targeted enrollment is 320 patients from both Italy and Taiwan. The Taiwan study plans to enroll a total of 120 patients and complete in June 2016.

On 18th December 2015, the first patient of this Taiwan study has been enrolled at the Chi-Mei Medical Center in Tainan.

"Although we have completed our Phase 2b enrolment in Europeans, we are excited to have enrolled our first patient of Chinese ethnicity for this Rostafuroxin study, which is targeted to treat high blood pressure that is associated with their genetic profiles" said Dr. Benjamin Li, Chief Executive Officer of the Group. "We are expecting to enroll more patients in Taiwan for this study, and we are eager to see how patients with specific genetic profiles respond to Rostafuroxin as compared to Losartan as a current standard of care".

About Rostafuroxin

Rostafuroxin is a digitoxigenin derivative that selectively disrupts the mutant adducin and the ouabain-activated Na(+)/K(+)-pump binding to Src-SH2 domain without affecting the binding of normal proteins. It is indicated for treatment of newly diagnosed hypertension patients who carry certain genetic profiles representative of adducin and Endogenous Oubain-hypertensive mechanisms. The personalized treatment of hypertension could signify a shift of paradigm in hypertension

treatment.

About Lee's Pharmaceutical

Lee's Pharm is a research-based biopharmaceutical company listed in Hong Kong with over 20 years operation in China's pharmaceutical industry. It is fully integrated with strong infrastructures in drug development, manufacturing, sales and marketing. It has established extensive partnership with over 20 international companies and currently has 14 products in the market place. Lee's Pharm focuses on several key disease areas such as cardiovascular diseases, oncology, gynecology, dermatology and ophthalmology. Lee's Pharm development program is lauded with 30 products stemming from both internal R&D efforts and collaborations with US, European and Japanese companies and aspires to combat diseases such as liver cancer and pulmonary hypertension. The mission of Lee's Pharm is to become a successful biopharmaceutical group in Asia providing innovative products to fight diseases and improve health and quality of life. Additional information is available at <http://www.leespharm.com>

About CVie

CVie is a joint venture between Lee's Pharmaceutical Holdings Ltd. and reputable US & Taiwan venture capitals. CVie is a stand-alone drug development company specialized in cardiovascular diseases. Currently, CVie owns two phase II assets that target cardiovascular disease with significant unmet medical need.

Safe Harbor Statement

The performance and the results of operation of Lee's during the past years are historical in nature and past performance can be no guarantee of future results of the Lee's. This news release may contain forward-looking statements and opinions that involve risks and uncertainties. Actual results may differ materially from expectations discussed in such forward-looking statements and opinions. Neither Lee's nor the Directors, employees or agents of Lee's assume (a) any obligation to correct or update the forward-looking statements or opinions contained in this news release; and (b) any liability in the event that any of the forward-looking statements or opinions does not materialise or turns out to be incorrect.

For further information, please contact:

Vivian Fung

Tel: (852)2314-1282

Fax: (852)2314-1708

Email: info@leespharm.com